|ZFIN ID: ZDB-PUB-180914-4|
Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma.
Mandelbaum, J., Shestopalov, I.A., Henderson, R.E., Chau, N.G., Knoechel, B., Wick, M.J., Zon, L.I.
|Source:||The Journal of experimental medicine 215(10): 2673-2685 (Journal)|
|Registered Authors:||Shestopalov, Ilya, Zon, Leonard I.|
|PubMed:||30209067 Full text @ J. Exp. Med.|
Mandelbaum, J., Shestopalov, I.A., Henderson, R.E., Chau, N.G., Knoechel, B., Wick, M.J., Zon, L.I. (2018) Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma.. The Journal of experimental medicine. 215(10):2673-2685.
ABSTRACTPluripotent cells have been used to probe developmental pathways that are involved in genetic diseases and oncogenic events. To find new therapies that would target MYB-driven tumors, we developed a pluripotent zebrafish blastomere culture system. We performed a chemical genetic screen and identified retinoic acid agonists as suppressors of c-myb expression. Retinoic acid treatment also decreased c-myb gene expression in human leukemia cells. Translocations that drive overexpression of the oncogenic transcription factor MYB are molecular hallmarks of adenoid cystic carcinoma (ACC), a malignant salivary gland tumor with no effective therapy. Retinoic acid agonists inhibited tumor growth in vivo in ACC patient-derived xenograft models and decreased MYB binding at translocated enhancers, thereby potentially diminishing the MYB positive feedback loop driving ACC. Our findings establish the zebrafish pluripotent cell culture system as a method to identify modulators of tumor formation, particularly establishing retinoic acid as a potential new effective therapy for ACC.